← Back to Search

Unknown

MYK-224 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index between 18 and 32 kg/m^2, inclusive, at screening.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 45 days
Awards & highlights

Study Summary

This trial looks into the effects of a drug on healthy men over 3 weeks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your body mass index (BMI) falls between 18 and 32 kg/m^2.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 45 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 45 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
Maximum observed concentration (Cmax)
Time to maximum observed concentration (Tmax)
Secondary outcome measures
Metabolite profiling of BMS-986435 in plasma, urine, and feces
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: MYK-224Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYK-224
2023
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,629 Previous Clinical Trials
4,126,309 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining opportunities to join this research endeavor?

"According to the clinicaltrials.gov webpage, this medical trial is still recruiting patients since its initial posting on January 16th of 2023 and last update in March 17th of same year."

Answered by AI

Does the trial accept applicants aged sixty or above?

"This trial specifically seeks patients aged 18 to 55. However, there are 54 clinical studies available for minors and 368 trials targeting seniors."

Answered by AI

How many participants are being welcomed into the experiment?

"Affirmative. The information posted on clinicaltrials.gov attests to this medical study's actively recruitment process, which was kickstarted on January 16th 2023 and recently updated March 17th 2023. 8 patients need to be sourced from a single location for the trial to commence."

Answered by AI

Has MYK-224 been granted clearance by the FDA?

"Our team at Power gave MYK-224 a score of 1 due to the fact that this Phase 1 trial has only limited evidence backing its safety and efficacy."

Answered by AI

Am I eligible to be a participant in this research endeavor?

"This trial is open to 8 individuals aged 18-55 who are in good health. Furthermore, these participants must have a documented LVEF of at least 60%, BMI between 18 and 32 kg/m^2, be male as determined by the investigator and sponsor, and possess acoustic windows that allow for accurate assessment of LV systolic activity from TTEs."

Answered by AI
~3 spots leftby Mar 2025